LivaNova PLC Ordinary Shares (LIVN)
NASDAQ: LIVN · Electromedical & Electrotherapeutic Apparatus · Gloucester,
Our rating: Positive
Call changed from Neutral to Positive at $89.99, moderate conviction, November 6, 2026.
Breaks if: The Positive call breaks if revenue growth decelerates to below 6% for two consecutive reported quarters, or if trailing free cash flow falls below $80M — either would signal the franchise is losing commercial momentum faster than the current multiple assumes. On the upside, revenue growth sustained above 14% for two consecutive quarters, or a demonstrated path to GAAP operating profitability on a quarterly run-rate, would prompt a reassessment toward Conviction.
Key figures
| Market value | $5.0B |
|---|---|
| Revenue, last 12 months | $1.5B |
| Net income, last 12 months | $196M |
| Free cash flow, last 12 months | $129M |
| Price to earnings | 25.5× |
| Free cash flow yield | 2.6% |
| Dividend yield | 0.0% |
| Operating margin | 10.7% |
| Return on equity | 15.5% |
| Beta to the S&P 500 | 0.89 |
| Volatility, annualized | 40.5% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $393M | 9.9% | $0.11 | $43M |
| June 30, 2026 | $391M | 10.8% | $1.93 | $35M |
| March 31, 2026 | $362M | 14.3% | $0.40 | $926000.00 |
| December 31, 2025 | $361M | 12.1% | $0.56 | $50M |
| September 30, 2025 | $358M | 12.5% | $0.49 | $62M |
| June 30, 2025 | $353M | 10.7% | $0.50 | $48M |
| March 31, 2025 | $317M | 7.4% | $-6.01 | $13M |
| December 31, 2024 | $322M | 3.8% | $1.03 | $68M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.40B: Claude 72%, Gemini 65%, Mistral 70%
- Diluted earnings per share are at least $0.56: Claude 52%, Gemini 30%, Mistral 55%
- Free cash flow for the quarter is at least $0.05B: Claude 55%, Gemini 55%, Mistral 50%
13 ledger entries and 71 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.